Posttransplant lymphomas

Jennifer A. Kanakry, Yvette L. Kasamon, Richard F Ambinder

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

PTLDs are a heterogeneous group of diseases ranging from reactive hyperplasia to malignant lymphoma that occur in patients after solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). PTLD can occur anywhere from weeks to decades after transplantation. Most are Epstein-Barr virus (EBV)-positive. In at least some instances, EBV gene expression appears to drive the lymphoproliferation in an environment of decreased cell-mediated immunity. Treatment may include reducing or changing immunosuppression, rituximab, adoptive T-cell therapy, or cytotoxic chemotherapy. Judicious selection of immunosuppressive agents, early intervention with rituximab, or utilization of EBVtargeted therapies is a promising prevention strategy.

Original languageEnglish (US)
Title of host publicationLymphoma
Subtitle of host publicationDiagnosis and Treatment
PublisherHumana Press Inc.
Pages267-277
Number of pages11
ISBN (Electronic)9781627034081
ISBN (Print)9781627034074
DOIs
StatePublished - Jan 1 2013

Keywords

  • Epstein-Barr virus (EBV)
  • Hematopoietic stem cell transplantation (HSCT)
  • Immune suppression
  • Posttransplantation lymphoproliferative disorders (PTLDs)
  • Solid organ transplantation (SOT)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Posttransplant lymphomas'. Together they form a unique fingerprint.

Cite this